Danaher Corporation (NYSE:DHR) Shares Sold by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC decreased its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 8.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 15,989 shares of the conglomerate's stock after selling 1,532 shares during the quarter. Daymark Wealth Partners LLC's holdings in Danaher were worth $3,278,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Fortis Capital Advisors LLC increased its holdings in Danaher by 1.3% during the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after purchasing an additional 50 shares during the period. Fayez Sarofim & Co grew its stake in shares of Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock worth $1,902,000 after purchasing an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC lifted its holdings in Danaher by 4.8% during the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after buying an additional 50 shares during the last quarter. Perennial Investment Advisors LLC boosted its holdings in Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after purchasing an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC lifted its position in shares of Danaher by 3.1% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after buying an additional 52 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Price Performance

NYSE DHR traded up $0.88 during trading hours on Thursday, reaching $201.88. The company's stock had a trading volume of 5,562,250 shares, compared to its average volume of 3,497,229. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The company's 50-day moving average is $194.31 and its two-hundred day moving average is $209.00. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The stock has a market cap of $144.48 billion, a PE ratio of 39.20, a PEG ratio of 2.77 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.63%. Danaher's payout ratio is currently 24.85%.

Insider Buying and Selling

In other news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DHR shares. Royal Bank Of Canada reiterated an "outperform" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Wolfe Research dropped their price objective on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a research note on Monday, April 7th. Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 price objective for the company in a research note on Friday, March 14th. The Goldman Sachs Group cut their price target on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Finally, Jefferies Financial Group lowered their target price on shares of Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $248.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.